Search the Newsreel

A Look at Aveanna Healthcare Holdings Inc (AVAH) After 9.2% Gain -- GF Value $5.20 vs Price $12.32

Aveanna Healthcare Holdings Inc (AVAH) recently saw a 9.2% stock gain, pushing its price to $12.32. However, GuruFocus estimates its intrinsic value (GF Value™) at $5.20, indicating significant overvaluation. The stock has an "Above Average" GF Score™ of 63/100, but is flagged for weak …

AVAH Q2 Earnings Call Highlights Higher Growth Targets

Aveanna Healthcare (NASDAQ:AVAH) Shares Gap Up Following Better-Than-Expected Earnings

Aveanna Healthcare (AVAH) shares gapped up after reporting better-than-expected earnings, with revenue rising 13.7% year over year to $670.5 million and adjusted EPS of $0.22, surpassing analyst estimates. The company also raised its 2026 guidance, projecting revenue above $2.68 billion and adjusted EBITDA above …

Deutsche Bank Adjusts Aveanna Healthcare PT to $16 From $11.50, Maintains Buy Rating

Deutsche Bank has increased its price target for Aveanna Healthcare Holdings Inc. (AVAH) to $16 from $11.50, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the bank regarding the company's valuation. Earlier the same day, UBS also …

Raymond James raises Aveanna Healthcare stock price target on strong results

Raymond James raised its price target on Aveanna Healthcare Holdings (NASDAQ:AVAH) to $15.00 from $13.00, maintaining a Strong Buy rating due to strong Q2 2026 results and an increased EBITDA guidance. The company also reported Q2 2026 revenue of $670.5 million, exceeding analyst forecasts, …

Aveanna stock hits 52-week high after Q2 beat (AVAH:NASDAQ)

Aveanna hits 52-week high after Q2 beat, guidance hike

[Close up image of wooden cubes with alphabet Q2 on office desk.] mohd izzuan Shares of Aveanna Healthcare (AVAH [https://seekingalpha.com/symbol/AVAH]) reached a new 52-week high on Thursday after the home healthcare provider reported better-than-expected Q2 2026 financials and raised its full-year outlook above the …

Aveanna Eyes Home Health, Hospice M&A While Executing Preferred Payer Strategy

Aveanna Healthcare Holdings (Nasdaq: AVAH) has surpassed its preferred payer goals and intends to expand its home health and hospice segment through strategic acquisitions. The company updated its organic growth rate for home health and hospice to 8-10% and anticipates achieving double-digit annual revenue …

Aveanna Healthcare: Q2 Earnings Report Boosts Stock And Reinforces My Buy Rating (AVAH)

Aveanna Healthcare (NASDAQ:AVAH) Issues Quarterly Earnings Results

Aveanna Steers Toward Hospice, Home Health Expansion

Aveanna Healthcare Holdings Inc. is strategically focusing on expanding its hospice and home health segments, despite high multiples in the M&A market for hospice. The company reported significant revenue growth across all three of its healthcare segments in Q2, with hospice and home health …

Aveanna Healthcare (NASDAQ:AVAH) Reaches New 52-Week High Following Strong Earnings

Aveanna (AVAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates

(AVAH) Aveanna Healthcare Expects 2026 Revenue Higher Than $2.68B, vs. FactSet Est of $2.63B

Aveanna Healthcare Holdings Inc. (AVAH) anticipates its 2026 revenue to exceed $2.68 billion, surpassing FactSet's estimate of $2.63 billion. This announcement comes alongside the release of their fiscal Q2 adjusted earnings and revenue, both of which have risen. The company also reported Q2 revenue …

Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance

Aveanna Healthcare Holdings (NASDAQ: AVAH) reported strong second-quarter 2026 financial results, with revenue increasing by 13.7% to $670.5 million and net income rising to $40.3 million. The company also increased its full-year 2026 guidance, projecting revenue greater than $2.68 billion and Adjusted EBITDA greater …

Aveanna AVAH Q2 Revenue Rises 13.7% to $670.5 Million

Aveanna Healthcare Holdings (AVAH) reported a 13.7% increase in second-quarter 2026 revenue, reaching $670.5 million, with net income rising to $40.3 million. The company also raised its full-year 2026 revenue guidance to over $2.68 billion and adjusted EBITDA guidance to over $365 million. Insider …

Aveanna Healthcare Holdings Q2 2026 Earnings Preview

* Aveanna Healthcare Holdings (AVAH [https://seekingalpha.com/symbol/AVAH]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is $0.17 [https://seekingalpha.com/symbol/AVAH/earnings/estimates] (+1600.0% Y/Y) and the consensus Revenue Estimate is $638.63M (+8.3% Y/Y). * Over the last 2 …

Aveanna Healthcare earnings up next as nine-quarter beat streak faces test

Aveanna Healthcare Holdings Inc. is scheduled to release its second-quarter earnings, and investors will be watching to see if the company can extend its nine-quarter streak of beating analyst expectations. Despite Wall Street forecasting sequential declines in revenue and profit due to seasonality, recent …

Janus Henderson Group PLC Lowers Stock Position in Aveanna Healthcare Holdings Inc. $AVAH

Janus Henderson Group PLC significantly reduced its stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by 91.6% in the first quarter, selling over 257,000 shares. Despite this, institutional investors collectively own a substantial 87.96% of AVAH. The company reported strong Q1 earnings, beating estimates with …

Aveanna Healthcare Holdings Inc (AVAH) Stock Analysis: Growth Potential Amid Strong Revenue Growth and Analyst Confidence

Will Lower PDS Margin Affect Aveanna Healthcare's Q2 Earnings?

Aveanna Healthcare Holdings Inc. (AVAH) is scheduled to report its second-quarter 2026 earnings on August 13. While revenue is projected to increase, the company's earnings per share are expected to see a slight year-over-year decrease, primarily due to an anticipated decline in the gross …

How Board Loss of Key Clinical Voice Will Impact Aveanna Healthcare Holdings (AVAH) Investors

Dr. Erica Schwartz, Chair of the Clinical Quality Committee, has resigned from Aveanna Healthcare Holdings' board after being appointed Director of the U.S. CDC. While her departure removes a key clinical voice, it doesn't immediately alter Aveanna's financial outlook, which is characterized by high …

Gear Up for Aveanna (AVAH) Q2 Earnings: Wall Street Estimates for Key Metrics

Aveanna Healthcare Holdings (AVAH) Board Director Erica Schwartz Resigns

The article reports that Erica Schwartz has resigned from her position as a Board Director at Aveanna Healthcare Holdings (AVAH). No further details regarding the resignation or its implications are provided within the given content.

Aveanna Healthcare Director Resigns Following CDC Appointment

Aveanna Healthcare Holdings announced that Dr. Erica Schwartz, a Class III independent director and Chair of the Clinical Quality Committee, resigned from its Board of Directors on August 5, 2026. Her resignation followed her nomination and confirmation as Director of the United States Centers …

Aveanna Healthcare Holdings Inc. Announces Resignation of Erica Schwartz as Class III Director, Effective August 5, 2026

Aveanna Healthcare Holdings Inc. announced that Dr. Erica Schwartz, a Class III director, resigned from the company's Board of Directors, effective August 5, 2026. Her resignation is due to her nomination and subsequent confirmation as the Director of the United States Centers of Disease …

Aveanna Healthcare Holdings (AVAH) Could Be 5% Undervalued On Its Preferred Payer Narrative

New CDC Director Schwartz Exits Aveanna Board

Dr. Erica Schwartz, the new director of the Centers for Disease Control and Prevention (CDC), has resigned from her position on the board of Aveanna Healthcare Holdings (Nasdaq: AVAH). This resignation is a direct result of her nomination and confirmation as CDC director, as …

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $10.78, surpassing its opening price of $9.33. The company exceeded quarterly earnings expectations, reporting $0.18 EPS against a $0.13 consensus and revenue of …

Aveanna Healthcare (AVAH) Expected to Announce Earnings on Thursday

Aveanna Healthcare (AVAH) holders tied to J.H. Whitney and Bain may control over 50%

A recent SEC filing (SCHEDULE 13G/A) for Aveanna Healthcare Holdings Inc. (AVAH) reveals that entities affiliated with J.H. Whitney, including PSA Healthcare Investment Holding LLC and J.H. Whitney VII, L.P., report significant beneficial ownership of Aveanna's common stock. Due to a Stockholders Agreement, the …

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Cytokinetics (CYTK)

This article highlights bullish sentiments from analysts on two healthcare companies: Labcorp Holdings (LH) and Cytokinetics (CYTK). William Blair analyst Jared Haase maintained a Buy rating on Labcorp Holdings, while H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics with a set …